Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

European Lung Cancer Congress - ELCC

March 26 - 29, 2025

Datopotamab Deruxtecan
Durvalumab
Osimertinib
Savolitinib
Savolitinib Osimertinib
Datopotamab Deruxtecan Osimertinib
Datopotamab Deruxtecan Rilvegostomig
Trastuzumab Deruxtecan Rilvegostomig

pdf

Effects of Datopotamab deruxtecan (Dato-DXd) vs. docetaxel on patient-reported outcomes (PROs) in adults with previously treated advanced or metastatic non squamous (NSQ) non-small cell lung cancer (NSCLC): results from TROPION-LUNG01

pdf

Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02.

pdf

Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN)

pdf

Sites of relapse and subsequent therapy in the BR.31 phase 3 study of durvalumab vs placebo in resected stage IB-IIIA NSCLC

pdf

Global qualitative assessment of factors affecting multidisciplinary team (MDT) care in early-stage NSCLC

pdf

An international multicentre open-label randomised phase III trial evaluating the benefit of adding adjuvant durvalumab after neoadjuvant chemo-immunotherapy in stage IIB-IIIB (N2) resectable NSCLC

pdf

Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): final data extraction from PACIFIC-R

pdf

Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis

pdf

First-line (1L) durvalumab (D) + platinum-etoposide (EP) in extensive-stage SCLC (ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE

ppt

Patient-reported outcomes (PROs) from the LAURA study: osimertinib (osi) in patients (pts) with unresectable (UR) EGFR-mutated (EGFRm) stage (stg) III NSCLC without progression after definitive chemoradiation (CRT)

pdf

Long-term survival outcomes with first line (1L) osimertinib monotherapy treatment in U.S. patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations

pdf

Characterisation of benefit-risk by pemetrexed (pem) exposure in patients (pts) with EGFRm aNSCLC treated with 1L osimertinib (osi) + platinum-pem in FLAURA2

pdf

Real-world patterns of patients with disease progression after first-line osimertinib for EGFRm aNSCLC in China (FLOURISH study)

pdf

Final overall survival and long-term safety outcomes of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 (METex14) mutation: An update from a Phase 3b study

ppt

SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and MET overexpression (OverExp) and/or amplification (AMP) following progressive disease (PD) on osi

ppt

Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

pdf

TROPION-Lung14: A Phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).

pdf

TROPION-Lung15: A Phase 3 study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib.

PDF

TROPION-Lung10: Phase 3 study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig for non-squamous (NSQ) advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)

pdf

Phase 1b open-label study of trastuzumab deruxtecan (T-DXd) + rilvegostomig ± carboplatin as first-line treatment for metastatic HER2-overexpressing (HER2-OE) non-small cell lung cancer (NSCLC): DESTINY-Lung03 Part 4

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização